Name | Number of supported studies | Average coverage | |
---|---|---|---|
fibroblast | 22 studies | 39% ± 18% | |
endothelial cell | 17 studies | 33% ± 15% | |
astrocyte | 16 studies | 39% ± 14% | |
oligodendrocyte | 15 studies | 41% ± 14% | |
oligodendrocyte precursor cell | 14 studies | 55% ± 23% | |
microglial cell | 14 studies | 41% ± 14% | |
endothelial cell of lymphatic vessel | 12 studies | 37% ± 13% | |
mesothelial cell | 10 studies | 35% ± 12% | |
pericyte | 9 studies | 35% ± 25% | |
smooth muscle cell | 8 studies | 28% ± 12% | |
retina horizontal cell | 7 studies | 70% ± 19% | |
retinal rod cell | 7 studies | 26% ± 11% | |
connective tissue cell | 6 studies | 32% ± 18% | |
GABAergic neuron | 6 studies | 31% ± 9% | |
myofibroblast cell | 6 studies | 32% ± 10% | |
macrophage | 5 studies | 22% ± 10% | |
podocyte | 4 studies | 48% ± 28% | |
endothelial cell of artery | 4 studies | 30% ± 8% | |
vein endothelial cell | 4 studies | 26% ± 9% | |
adventitial cell | 4 studies | 33% ± 10% | |
Mueller cell | 4 studies | 37% ± 15% | |
glomerular endothelial cell | 3 studies | 18% ± 1% | |
extravillous trophoblast | 3 studies | 51% ± 23% | |
epithelial cell | 3 studies | 30% ± 18% | |
endothelial cell of vascular tree | 3 studies | 22% ± 5% | |
capillary endothelial cell | 3 studies | 22% ± 10% | |
interneuron | 3 studies | 30% ± 12% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 97% | 17118.85 | 2568 / 2642 | 100% | 858.07 | 705 / 705 |
breast | 100% | 14165.17 | 459 / 459 | 95% | 423.14 | 1059 / 1118 |
kidney | 100% | 11545.93 | 89 / 89 | 87% | 287.57 | 783 / 901 |
ovary | 100% | 27740.30 | 180 / 180 | 81% | 165.74 | 350 / 430 |
thymus | 94% | 5524.98 | 613 / 653 | 86% | 142.16 | 519 / 605 |
uterus | 99% | 13853.14 | 168 / 170 | 80% | 195.46 | 368 / 459 |
adrenal gland | 86% | 4169.50 | 222 / 258 | 93% | 262.51 | 213 / 230 |
liver | 85% | 7471.24 | 192 / 226 | 83% | 174.35 | 336 / 406 |
lung | 88% | 4578.30 | 511 / 578 | 79% | 131.62 | 913 / 1155 |
bladder | 100% | 8657.90 | 21 / 21 | 64% | 127.76 | 325 / 504 |
prostate | 91% | 5492.67 | 224 / 245 | 68% | 69.55 | 339 / 502 |
skin | 99% | 13505.52 | 1786 / 1809 | 57% | 146.59 | 271 / 472 |
esophagus | 74% | 5702.24 | 1076 / 1445 | 70% | 106.59 | 128 / 183 |
intestine | 83% | 7499.75 | 805 / 966 | 57% | 92.72 | 302 / 527 |
pancreas | 19% | 651.85 | 61 / 328 | 94% | 307.51 | 168 / 178 |
stomach | 46% | 4311.89 | 166 / 359 | 65% | 101.94 | 185 / 286 |
ureter | 0% | 0 | 0 / 0 | 100% | 232.04 | 1 / 1 |
blood vessel | 100% | 25734.74 | 1333 / 1335 | 0% | 0 | 0 / 0 |
adipose | 100% | 15973.31 | 1202 / 1204 | 0% | 0 | 0 / 0 |
heart | 71% | 3337.26 | 609 / 861 | 0% | 0 | 0 / 0 |
spleen | 63% | 2753.55 | 151 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 62% | 105.03 | 28 / 45 |
eye | 0% | 0 | 0 / 0 | 60% | 126.32 | 48 / 80 |
lymph node | 0% | 0 | 0 / 0 | 21% | 21.12 | 6 / 29 |
muscle | 9% | 364.96 | 71 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 9.43 | 3 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0060718 | Biological process | chorionic trophoblast cell differentiation |
GO_0030512 | Biological process | negative regulation of transforming growth factor beta receptor signaling pathway |
GO_0012501 | Biological process | programmed cell death |
GO_0030514 | Biological process | negative regulation of BMP signaling pathway |
GO_0001890 | Biological process | placenta development |
GO_0006508 | Biological process | proteolysis |
GO_0043065 | Biological process | positive regulation of apoptotic process |
GO_0005615 | Cellular component | extracellular space |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0070062 | Cellular component | extracellular exosome |
GO_0062023 | Cellular component | collagen-containing extracellular matrix |
GO_0005829 | Cellular component | cytosol |
GO_0140677 | Molecular function | molecular function activator activity |
GO_0042802 | Molecular function | identical protein binding |
GO_0008236 | Molecular function | serine-type peptidase activity |
GO_0019838 | Molecular function | growth factor binding |
GO_0005515 | Molecular function | protein binding |
GO_0004252 | Molecular function | serine-type endopeptidase activity |
Gene name | HTRA1 |
Protein name | HtrA serine peptidase 1 HTRA1 protein Serine protease HTRA1 (EC 3.4.21.-) (High-temperature requirement A serine peptidase 1) (L56) (Serine protease 11) |
Synonyms | PRSS11 HTRA |
Description | FUNCTION: Serine protease with a variety of targets, including extracellular matrix proteins such as fibronectin. HTRA1-generated fibronectin fragments further induce synovial cells to up-regulate MMP1 and MMP3 production. May also degrade proteoglycans, such as aggrecan, decorin and fibromodulin. Through cleavage of proteoglycans, may release soluble FGF-glycosaminoglycan complexes that promote the range and intensity of FGF signals in the extracellular space. Regulates the availability of insulin-like growth factors (IGFs) by cleaving IGF-binding proteins. Inhibits signaling mediated by TGF-beta family members. This activity requires the integrity of the catalytic site, although it is unclear whether TGF-beta proteins are themselves degraded. By acting on TGF-beta signaling, may regulate many physiological processes, including retinal angiogenesis and neuronal survival and maturation during development. Intracellularly, degrades TSC2, leading to the activation of TSC2 downstream targets. . |
Accessions | Q92743 ENST00000648167.1 Q05DJ8 A0A3B3IU24 ENST00000420892.1 H0Y7G9 ENST00000368984.8 |